Jim Palma and John Hopper, Co-Chairs of NORD Rare Cancer Coalition, explain the difference between genetic testing and genomic profile testing, and why all patients with rare cancers should have a genomic profile done to select the best treatment for them based on potential genomic alteration.
By Dan Dean
Non-Hodgkin lymphoma survivor Dan Dean spoke with several experts about the advances in genomic testing, which have enabled oncologists to treat patients with new “targeted therapies” that fight cancer based on the specific features of a tumor.
ImmunotherapyLung CancerPatient StoriesGenomic Testing
Christie Bevington shares her story of how immunotherapy was the only treatment that helped stop her cancer progression and relieve her back pain caused by lung cancer.
ImmunotherapyMolecular TestingGenomic Testing
Tim Dorius, MD, explains the role of molecular profiling in relation to immunotherapy, and how oncologists can now look at the genetic makeup of a tumor to identify specific mutations or other biomarkers.
BiomarkersGenetics & CancerGenomic Testing
By Wayne Kuznar
Genetic testing, genomic testing, molecular profiling—how can you make sense of these terms to ensure you receive the best test and best treatment in this era of targeted therapies? A group of experts and patient advocates provide answers to these questions.
BiomarkersCholangiocarcinomaGenetics & CancerGenomic Testing
By Wayne Kuznar
New treatments are becoming available for patients with cholangiocarcinoma (bile duct cancer). Testing for specific biomarkers is crucial to ensure each patient receives the best available treatment for any associated biomarker.
Results 1 - 6 of 6